D-3263 is an agonist of transient receptor potential melastatin member 8 (TRPM8) with potential antineoplastic activity.

Product information

CAS Number: 947257-66-1

Molecular Weight: 373.49

Formula: C21H31N3O3

Chemical Name: 3-(2-aminoethyl)-5-methoxy-1-[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexanecarbonyl]-2,3-dihydro-1H-1,3-benzodiazol-2-one

Smiles: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1C(=O)N1C2=CC=C(C=C2N(CCN)C1=O)OC

InChiKey: ZGTYTFYRCIRWBL-HYVNUMGLSA-N

InChi: InChI=1S/C21H31N3O3/c1-13(2)16-7-5-14(3)11-17(16)20(25)24-18-8-6-15(27-4)12-19(18)23(10-9-22)21(24)26/h6,8,12-14,16-17H,5,7,9-11,22H2,1-4H3/t14-,16+,17-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

D-3263 induces calcium flux and cell death in in vitro cells expressing TRPM8.

In Vivo:

D-3263 (50 or 100 mg/kg/d) alone or with Finasteride (10 mg/kg/d) results in reduction in prostate hyperplasia of rats with evidence of a dose response. The highest dose of the TRPM8 agonist D-3263, given in combination with Finasteride, results in lower prostate weights than the highest dose of D-3263 or Finasteride given alone, suggesting a potential additive effect.

Products are for research use only. Not for human use.